Business
Operational Update
Operational Update.
About this update from Verici Dx Plc
[{"type":"text","content":"\n \n \n \n Verici Dx plc\n \n \n \n \n (\"Verici Dx\" or the \"Company\")\n \n \n \n \n \n \n \n \n \n Operational Update\n \n \n \n \n \n \n \n \n \n First revenues from Tutivia\n \n \n ™\n \n \n following full commercial launch\n \n \n \n \n \n \n Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant,\n provides an update on its operational progress made since the release of its interim results in September 2022.\n \n \n \n \n \n Verici Dx\n continues to execute the commercial introduction of Tutivia™, the Company's first product for kidney transplant rejection, with first revenues in FY 2023 and is exploring strategic options to increase sales distribution and launch its second lead product, Clarava™ by the end of the year. The Company retains sufficient funding to achieve further key milestones in 2023 and the first half of 2024, which will support commercial adoption including the publication of additional data and obtaining both Medicare and private payor pricing and coverage.\n \n \n \n \n \n \n \n \n Data continues to support product differentiation and competitive advantages\n \n \n \n Following a robust validation trial using a varied, 'all-comers' patient population in a clinical setting, Tutivia™, a\n post-transplant prognostic test for the assessment of risk of acute kidney\n rejection\n , was pilot-launched in December 2022 ahead of its full commercial launch in January 2023. The validation trial data showed a positive predictive value (PPV) of 60%, over three times that was achieved by the closest comparative product in the market when used in the same context, establishing a new industry standard. Additionally, study data analysis of the clinical performance of Tutivia™ demonstrated a differentiation of high-risk and low-risk patient groups, determining that patients of high risk were approximately six times more likely to have a rejection than those of low risk. This represents a significant demonstration of TutiviaTM as a predictive test capable of informing a clear, actionable response from clinicians. The Directors believe that no other comparable products have been validated to this degree.\n \n \n \n \n \n Tutivia™ also has competitive advantages, as it can be run as early as the first-week post-transplant, earlier than any other te...